News Website

Merck's Keytruda plus chemo comes up short as post-surgery therapy in newly diagnosed endometrial cancer - FiercePharma

Merck's Keytruda plus chemo comes up short as post-surgery therapy in newly diagnosed endometrial cancer FiercePharma

Published: May 9, 2024, 7 a.m.

Read Full Article

‘My husband had to sign permission for my hysterectomy when I was 30’ - The Telegraph

‘My husband had to sign permission for my hysterectomy when I was 30’ The Telegraph

Published: May 6, 2024, 7 a.m.

Read Full Article

GLAMOUR Women in Charge: Meet Founder of Honest Hormones, Giada Bertola - Glamour S.A.

GLAMOUR Women in Charge: Meet Founder of Honest Hormones, Giada Bertola Glamour S.A.

Published: May 2, 2024, 7 a.m.

Read Full Article

Former Liberal MP Nicolle Flint to recontest Adelaide seat of Boothby at next federal election - ABC News

Former Liberal MP Nicolle Flint to recontest Adelaide seat of Boothby at next federal election ABC News

Published: May 1, 2024, 7 a.m.

Read Full Article

Former Tetbury mayor Ann Pearce admits falsely claiming benefits - BBC.com

Former Tetbury mayor Ann Pearce admits falsely claiming benefits BBC.com

Published: April 29, 2024, 7 a.m.

Read Full Article

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting - PR Newswire

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting PR Newswire

Published: April 24, 2024, 7 a.m.

Read Full Article

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting - Investor Relations | Karyopharm Therapeutics

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting Investor Relations | Karyopharm Therapeutics

Published: April 24, 2024, 7 a.m.

Read Full Article

Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses - Nature.com

Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses Nature.com

Published: April 23, 2024, 7 a.m.

Read Full Article

Could this be a transformative year for women’s health? - Bill & Melinda Gates Foundation

Could this be a transformative year for women’s health? Bill & Melinda Gates Foundation

Published: April 17, 2024, 7 a.m.

Read Full Article

Danielle Collins: Laura Robson explains why in-form American has put her health before tennis - Sky Sports

Danielle Collins: Laura Robson explains why in-form American has put her health before tennis Sky Sports

Published: April 15, 2024, 7 a.m.

Read Full Article

Latest Articles

Merck's Keytruda plus chemo comes up short as post-surgery therapy in newly diagnosed endometrial cancer - FiercePharma

‘My husband had to sign permission for my hysterectomy when I was 30’ - The Telegraph

GLAMOUR Women in Charge: Meet Founder of Honest Hormones, Giada Bertola - Glamour S.A.

Former Liberal MP Nicolle Flint to recontest Adelaide seat of Boothby at next federal election - ABC News

Former Tetbury mayor Ann Pearce admits falsely claiming benefits - BBC.com

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting - PR Newswire

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting - Investor Relations | Karyopharm Therapeutics

Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses - Nature.com

Could this be a transformative year for women’s health? - Bill & Melinda Gates Foundation

Danielle Collins: Laura Robson explains why in-form American has put her health before tennis - Sky Sports

Subscribe to Our Newsletter